These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 16687314)

  • 1. Therapeutic potential of melatonin ligands.
    Delagrange P; Boutin JA
    Chronobiol Int; 2006; 23(1-2):413-8. PubMed ID: 16687314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential.
    Zlotos DP; Jockers R; Cecon E; Rivara S; Witt-Enderby PA
    J Med Chem; 2014 Apr; 57(8):3161-85. PubMed ID: 24228714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-throughput screening assay for new ligands at human melatonin receptors.
    Yan JH; Su HR; Boutin JA; Renard MP; Wang MW
    Acta Pharmacol Sin; 2008 Dec; 29(12):1515-21. PubMed ID: 19026172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in melatonin receptor ligands.
    Zlotos DP
    Arch Pharm (Weinheim); 2005 Jun; 338(5-6):229-47. PubMed ID: 15952241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme.
    Mailliet F; Ferry G; Vella F; Berger S; Cogé F; Chomarat P; Mallet C; Guénin SP; Guillaumet G; Viaud-Massuard MC; Yous S; Delagrange P; Boutin JA
    Biochem Pharmacol; 2005 Dec; 71(1-2):74-88. PubMed ID: 16293234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melatonin as a naturally occurring co-substrate of quinone reductase-2, the putative MT3 melatonin membrane receptor: hypothesis and significance.
    Tan DX; Manchester LC; Terron MP; Flores LJ; Tamura H; Reiter RJ
    J Pineal Res; 2007 Nov; 43(4):317-20. PubMed ID: 17910598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the development of melatonin MT(1) and MT(2) receptor agonists.
    Mor M; Rivara S; Pala D; Bedini A; Spadoni G; Tarzia G
    Expert Opin Ther Pat; 2010 Aug; 20(8):1059-77. PubMed ID: 20533893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melatonin receptors in the eye: location, second messengers and role in ocular physiology.
    Alarma-Estrany P; Pintor J
    Pharmacol Ther; 2007 Mar; 113(3):507-22. PubMed ID: 17229466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are G protein-coupled receptor heterodimers of physiological relevance?--Focus on melatonin receptors.
    Levoye A; Jockers R; Ayoub MA; Delagrange P; Savaskan E; Guillaume JL
    Chronobiol Int; 2006; 23(1-2):419-26. PubMed ID: 16687315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New ligands at the melatonin binding site MT(3).
    Boussard MF; Truche S; Rousseau-Rojas A; Briss S; Descamps S; Droual M; Wierzbicki M; Ferry G; Audinot V; Delagrange P; Boutin JA
    Eur J Med Chem; 2006 Mar; 41(3):306-20. PubMed ID: 16414149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homology modeling of MT1 and MT2 receptors.
    Farce A; Chugunov AO; Logé C; Sabaouni A; Yous S; Dilly S; Renault N; Vergoten G; Efremov RG; Lesieur D; Chavatte P
    Eur J Med Chem; 2008 Sep; 43(9):1926-44. PubMed ID: 18255198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity.
    Lucini V; Pannacci M; Scaglione F; Fraschini F; Rivara S; Mor M; Bordi F; Plazzi PV; Spadoni G; Bedini A; Piersanti G; Diamantini G; Tarzia G
    J Med Chem; 2004 Aug; 47(17):4202-12. PubMed ID: 15293992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel quantitative structure-activity relationship method to predict the affinities of MT3 melatonin binding site.
    Du H; Wang J; Zhang X; Hu Z
    Eur J Med Chem; 2008 Dec; 43(12):2861-9. PubMed ID: 18400335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Melatonin binding site MT3 is QR2: state of the art].
    Boutin JA
    J Soc Biol; 2007; 201(1):97-103. PubMed ID: 17762829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melatonin: pharmacological aspects and clinical trends.
    Rios ER; Venâncio ET; Rocha NF; Woods DJ; Vasconcelos S; Macedo D; Sousa FC; Fonteles MM
    Int J Neurosci; 2010 Sep; 120(9):583-90. PubMed ID: 20707632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic actions of melatonin in cancer: possible mechanisms.
    Srinivasan V; Spence DW; Pandi-Perumal SR; Trakht I; Cardinali DP
    Integr Cancer Ther; 2008 Sep; 7(3):189-203. PubMed ID: 18815150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands.
    Rivara S; Lodola A; Mor M; Bedini A; Spadoni G; Lucini V; Pannacci M; Fraschini F; Scaglione F; Sanchez RO; Gobbi G; Tarzia G
    J Med Chem; 2007 Dec; 50(26):6618-26. PubMed ID: 18052314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melatonin: Nature's most versatile biological signal?
    Pandi-Perumal SR; Srinivasan V; Maestroni GJ; Cardinali DP; Poeggeler B; Hardeland R
    FEBS J; 2006 Jul; 273(13):2813-38. PubMed ID: 16817850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular tools to study melatonin pathways and actions.
    Boutin JA; Audinot V; Ferry G; Delagrange P
    Trends Pharmacol Sci; 2005 Aug; 26(8):412-9. PubMed ID: 15992934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new perspective in Oral health: potential importance and actions of melatonin receptors MT1, MT2, MT3, and RZR/ROR in the oral cavity.
    Cutando A; Aneiros-Fernández J; López-Valverde A; Arias-Santiago S; Aneiros-Cachaza J; Reiter RJ
    Arch Oral Biol; 2011 Oct; 56(10):944-50. PubMed ID: 21459362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.